# Phase 3 hypertension trials recruiting: 57 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 57 trials in phase 3 for hypertension that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 hypertension trials: 57 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/hypertension

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 57
- Recruiting or not yet: 57
- Read on: November 19, 2026

## Trials

The 25 newest of 57, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 5, 2026 | NCT07919405 | A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Hypertension, Obesity | 1,408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919405) |
| September 24, 2026 | NCT07839585 | A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure... | Merck Sharp & Dohme LLC | Phase 3 | Not yet recruiting | Pulmonary Hypertension | 352 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07839585) |
| September 11, 2026 | NCT07816185 | A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier) | Pulmovant, Inc. | Phase 3 | Recruiting | Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases, Fibrosis | 376 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816185) |
| September 8, 2026 | NCT07806279 | Lifestyle Changes, Mushroom Supplementation, and Bupropion to Reduce Adiposity and Cardiometabolic Risk | Uppsala University | Phase 3 | Not yet recruiting | Cardiometabolic Syndrome, Obesity and Cardiovascular Risk, Overweight , Obesity | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07806279) |
| September 3, 2026 | NCT07801599 | Huayu Jiedu Formula (FTFY-919) Granules Versus Traditional Decoction for Acute Hypertensive Intracerebral Hemorrhage | Guangzhou University of Traditional Chinese Medicine | Phase 3 | Not yet recruiting | Intracerebral Hemorrhage, Hypertension | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801599) |
| August 5, 2026 | NCT07746271 | Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST... | The George Washington University Biostatistics Center | Phase 3 | Not yet recruiting | Hypertension in Pregnancy, Obstetrical Complications | 4,120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07746271) |
| July 9, 2026 | NCT07691515 | Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic... | Zhejiang Cancer Hospital | Phase 3 | Not yet recruiting | Intrahepatic Cholangiocarcinoma (Icc) | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691515) |
| June 23, 2026 | NCT07662759 | \[KJ-TFC-005\] Phase 3 Study, Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension | Kukje Pharma | Phase 3 | Recruiting | Glaucoma Open-Angle Primary, Ocular Hypertension | 188 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662759) |
| June 22, 2026 | NCT07661329 | A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension | YS Life Science Co., Ltd. | Phase 3 | Recruiting | Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH) | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07661329) |
| June 22, 2026 | NCT07660796 | A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension | Hanmi Pharmaceutical Company Limited | Phase 3 | Not yet recruiting | Hypertension | 256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07660796) |
| June 8, 2026 | NCT07632898 | Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH) | Inhibikase Therapeutics | Phase 3 | Not yet recruiting | Pulmonary Arterial Hypertension (PAH) | 484 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07632898) |
| June 1, 2026 | NCT07618806 | A Clinical Study Comparing Ankle Swelling Caused by Two Different Blood Pressure Medications, Levamlodipine and Amlodipine, in... | Zentiva, k.s. | Phase 3 | Not yet recruiting | Hypertension, Oedema | 344 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07618806) |
| June 1, 2026 | NCT07617532 | Efficacy and Safety of DNN.31.19.026 for Ocular Hypertension or Primary Open-Angle Glaucoma | Ache Laboratorios Farmaceuticos S.A. | Phase 3 | Not yet recruiting | Ocular Hypertension, Primary Open Angle Glaucoma | 336 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07617532) |
| May 29, 2026 | NCT07613099 | Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | Recruiting | Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation, Interstitial Lung Disease, Acute Lung Injury... | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07613099) |
| May 29, 2026 | NCT07612657 | A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations | VIVUS LLC | Phase 3 | Not yet recruiting | Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO... | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07612657) |
| May 1, 2026 | NCT07562477 | Efficacy of Remote Ischemic Conditioning for Hypertension in High-Altitude Immigrant Populations | Capital Medical University | Phase 3 | Not yet recruiting | Hypertension | 184 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07562477) |
| April 27, 2026 | NCT07552389 | Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in... | Hanlim Pharm. Co., Ltd. | Phase 3 | Recruiting | Hypertension, Diabete Type 2 | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07552389) |
| March 27, 2026 | NCT07495852 | Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant | Glaukos Corporation | Phase 3 | Recruiting | Glaucoma | 510 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07495852) |
| March 19, 2026 | NCT07481981 | A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary... | Insmed Incorporated | Phase 3 | Recruiting | Pulmonary Arterial Hypertension | 344 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07481981) |
| January 26, 2026 | NCT07365332 | An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH) | Inhibikase Therapeutics | Phase 3 | Recruiting | Pulmonary Arterial Hypertension | 486 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07365332) |
| January 13, 2026 | NCT07335211 | Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension | Huons Co., Ltd. | Phase 3 | Recruiting | Primary Open Angle Glaucoma (POAG), Ocular Hypertension | 206 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07335211) |
| January 9, 2026 | NCT07328919 | Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma... | TransThera Sciences (Nanjing), Inc. | Phase 3 | Not yet recruiting | Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07328919) |
| December 16, 2025 | NCT07285655 | A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD | Liquidia Technologies, Inc. | Phase 3 | Recruiting | Pulmonary Hypertension Due to Lung Disease (Disorder) | 344 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285655) |
| November 24, 2025 | NCT07245680 | COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities | Assistance Publique - Hôpitaux de Paris | Phase 3 | Recruiting | Pulmonary Arterial Hypertension (PAH), Comorbidities, Cardiovascular Disease (CVD) | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07245680) |
| November 18, 2025 | NCT07234032 | An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With... | Insmed Incorporated | Phase 3 | Recruiting | Pulmonary Hypertension, Interstitial Lung Disease | 344 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07234032) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Insmed Incorporated](https://specstream.ai/data/clinical-trials/company/insmed-incorporated) | 3 |
| Assistance Publique - Hôpitaux de Paris | 2 |
| Inhibikase Therapeutics | 2 |
| SpyGlass Pharma, Inc. | 2 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 1 |
| [Chong Kun Dang Pharmaceutical](https://specstream.ai/data/clinical-trials/company/chong-kun-dang-pharmaceutical) | 1 |
| [Hanlim Pharm. Co., Ltd.](https://specstream.ai/data/clinical-trials/company/hanlim-pharm-co-ltd) | 1 |
| University of Arizona | 1 |
| [Hanmi Pharmaceutical Company Limited](https://specstream.ai/data/clinical-trials/company/hanmi-pharmaceutical-company-limited) | 1 |
| Women and Infants Hospital of Rhode Island | 1 |
| Zentiva, k.s. | 1 |
| Guangzhou University of Traditional Chinese Medicine | 1 |
| National University Hospital, Singapore | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| Pulmovant, Inc. | 1 |
| Liquidia Technologies, Inc. | 1 |
| Amneal Pharmaceuticals, LLC | 1 |
| Wuhan Createrna Science and Technology Co., Ltd | 1 |
| University of Pittsburgh | 1 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 1 |
| Instituto de Investigación Sanitaria Aragón | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| Mayo Clinic | 1 |
| AOP Orphan Pharmaceuticals AG | 1 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 28 |
| South Korea | 18 |
| France | 11 |
| Spain | 11 |
| Belgium | 10 |
| Australia | 9 |
| Germany | 9 |
| Argentina | 8 |
| Canada | 8 |
| Italy | 8 |
| Japan | 8 |
| United Kingdom | 8 |
| China | 7 |
| Poland | 7 |
| Brazil | 6 |
| Czechia | 6 |
| Denmark | 6 |
| Hungary | 6 |
| Israel | 6 |
| Netherlands | 6 |
| Portugal | 6 |
| Taiwan | 6 |
| Austria | 5 |
| Bulgaria | 5 |
| Colombia | 5 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Bathtub and sink repair companies in the United States](https://specstream.ai/data/businesses/bathtub-and-sink-repair-companies/united-states)
- [Glass companies in the United States](https://specstream.ai/data/businesses/glass-companies/united-states)
- [Portuguese restaurants in the United States](https://specstream.ai/data/businesses/portuguese-restaurants/united-states)
- [Appliance repair companies in the United States](https://specstream.ai/data/businesses/appliance-repair-companies/united-states)
- [Engineering schools in the United States](https://specstream.ai/data/businesses/engineering-schools/united-states)
- [Nursing services in the United States](https://specstream.ai/data/businesses/nursing-services/united-states)
